title: Sorafenib-induced erythema multiforme for metastatic renal cell carcinoma.
authors.affiliation: Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research.
authors.forename: M
authors.initials: M
authors.lastname: Kodaira
authors.affiliation: Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research. Electronic address: stakahas@jfcr.or.jp.
authors.forename: S
authors.initials: S
authors.lastname: Takahashi
authors.affiliation: Department of Pathology.
authors.forename: K
authors.initials: K
authors.lastname: Takeuchi
authors.affiliation: Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research.
authors.forename: T
authors.initials: T
authors.lastname: Yuasa
authors.affiliation: Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research.
authors.forename: T
authors.initials: T
authors.lastname: Saotome
authors.affiliation: Department of Urology, Cancer Institute of Japanese Foundation for Cancer Research, Tokyo, Japan.
authors.forename: J
authors.initials: J
authors.lastname: Yonese
authors.affiliation: Department of Urology, Cancer Institute of Japanese Foundation for Cancer Research, Tokyo, Japan.
authors.forename: I
authors.initials: I
authors.lastname: Fukui
authors.affiliation: Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research.
authors.forename: K
authors.initials: K
authors.lastname: Hatake
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D004892:Erythema Multiforme / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000473:pathology / Q000556:secondary; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects*; D000077157:Sorafenib; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib